Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Systematic evaluation and optimization of immune-targeting modalities for glioblastoma
EF 2019-20
Résumé
"Glioblastoma (GBM) is one of the most common brain tumors in adults. Despite a very aggressive standard-of-care that includes radiation and chemotherapy, patients only live to a median of 15 months, with only 5% living up to five years. This may be because of an unimaginable degree of variability found across the tumor that is thought to be created by a small population of cells. Known as brain tumor-initiating cells (BTICs), this population is marked by a certain molecule called CD133. The presence of CD133 has been shown to correlate with poor patient prognosis, metastases, relapse and worse overall survival in GBM. We thus created a novel immunotherapy targeting these CD133-expressing cells called a chimeric antigen receptor (CAR) T-cell. CAR-Ts are generated from a patient's own T-cells, and are engineered to attack the tumor by recognizing molecules on tumor cells such as CD133. Our CD133-targeting CAR-T (CART133) has shown great killing efficacy and prolonged survival in our mouse model system of human tumors. However, generation of CAR-Ts may be difficult as it requires sufficient numbers of a cancer patient's own T-cells, since they may be immunocompromised after first-line therapy. Thus, we propose to make CAR-Ts that target CD133 (AlloCART133) from healthy donor T-cells. AlloCAR-T cells are genetically-edited to avoid attacking the recipient's tissues and/or be eliminated by the recipient while still maintaining their ability to attack the tumor. Therefore, AlloCART133 is an exciting new strategy that can provide a faster, more readily available therapy for patients with GBM."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429090
Name
Salim Sabra K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Systematic evaluation and optimization of immune-targeting modalities for glioblastoma
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allogenic; Biochemistry; Car-T; Crispr; Gbm; Gene-Editing; Immunotherapy; Oncology
Abstract
"Glioblastoma (GBM) is one of the most common brain tumors in adults. Despite a very aggressive standard-of-care that includes radiation and chemotherapy, patients only live to a median of 15 months, with only 5% living up to five years. This may be because of an unimaginable degree of variability found across the tumor that is thought to be created by a small population of cells. Known as brain tumor-initiating cells (BTICs), this population is marked by a certain molecule called CD133. The presence of CD133 has been shown to correlate with poor patient prognosis, metastases, relapse and worse overall survival in GBM. We thus created a novel immunotherapy targeting these CD133-expressing cells called a chimeric antigen receptor (CAR) T-cell. CAR-Ts are generated from a patient's own T-cells, and are engineered to attack the tumor by recognizing molecules on tumor cells such as CD133. Our CD133-targeting CAR-T (CART133) has shown great killing efficacy and prolonged survival in our mouse model system of human tumors. However, generation of CAR-Ts may be difficult as it requires sufficient numbers of a cancer patient's own T-cells, since they may be immunocompromised after first-line therapy. Thus, we propose to make CAR-Ts that target CD133 (AlloCART133) from healthy donor T-cells. AlloCAR-T cells are genetically-edited to avoid attacking the recipient's tissues and/or be eliminated by the recipient while still maintaining their ability to attack the tumor. Therefore, AlloCART133 is an exciting new strategy that can provide a faster, more readily available therapy for patients with GBM."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Salim, Sabra K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~